What's Happening?
Galderma has received approval from the U.S. Food and Drug Administration (FDA) to market its Differin Epiduo Acne Gel as an over-the-counter (OTC) product. This gel, which combines adapalene, a third-generation
retinoid, with benzoyl peroxide, was previously available only by prescription. The approval marks a significant shift in acne care, allowing consumers aged 12 and older to access a dermatologist-recommended, prescription-strength treatment without needing a prescription. The formulation is designed to address multiple causes of acne, such as clogged pores, acne-causing bacteria, and inflammation, offering a comprehensive solution for acne sufferers. The product will be available at major retailers like Walmart, Ulta, Target, and Amazon starting in the summer of 2026.
Why It's Important?
This FDA approval is a pivotal development in the acne treatment market, as it expands access to a proven, effective treatment for millions of individuals who suffer from acne. By transitioning from prescription to OTC, Galderma is making it easier for consumers to obtain a high-quality acne treatment, potentially improving adherence to treatment regimens and outcomes. This move also underscores Galderma's leadership in dermatology, particularly in retinoid science, and its commitment to advancing accessible skincare solutions. The broader availability of Differin Epiduo could lead to increased competition in the OTC acne treatment market, potentially driving innovation and price adjustments.
What's Next?
With the OTC launch of Differin Epiduo, Galderma is poised to strengthen its position in the acne care market. The company plans to continue leveraging its scientific expertise to expand its product offerings and reach a wider audience. As the product becomes available, consumer response and market dynamics will be closely monitored. Dermatologists and healthcare professionals may also play a role in educating patients about the benefits and proper use of this newly accessible treatment. Additionally, Galderma's strategy may influence other pharmaceutical companies to consider similar prescription-to-OTC transitions for their products.
